NASDAQ:CPIX Cumberland Pharmaceuticals Q3 2026 Earnings Date & Estimates $7.25 +0.08 (+1.12%) As of 12:00 PM Eastern This is a fair market value price provided by Massive. Learn more. Cumberland Pharmaceuticals is estimated to report Q3 2026 earnings on Tuesday, November 3, 2026, before market opens. The conference call is scheduled for 4:30 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 3, 2026TimeBefore Market OpensConference Call4:30 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Cumberland Pharmaceuticals in Q3 2026Cumberland Pharmaceuticals is expected to post earnings of -$0.13 per share on revenue of $8.50 million. In the same quarter a year earlier Cumberland Pharmaceuticals reported -$0.06 per share on revenue of $8.29 million. Cumberland Pharmaceuticals last reported on August 4, 2026, posting -$0.20 per share and missing the -$0.13 consensus estimate.Consensus EstimatesConsensus EPS-$0.13Expected Revenue$8.50 millionPrior-Year EPS-$0.06Prior-Year Revenue$8.29 millionExpected Revenue Growth+2.5%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.20 (Missed by -$0.07)Last Quarter Revenue$0.17 millionPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ3 2025 Earnings Report Cumberland Pharmaceuticals Q3 2026 Earnings FAQ When does Cumberland Pharmaceuticals report Q3 2026 earnings? Cumberland Pharmaceuticals (NASDAQ:CPIX) is estimated to report Q3 2026 earnings on Tuesday, November 3, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Cumberland Pharmaceuticals' Q3 2026 earnings call? Cumberland Pharmaceuticals' Q3 2026 earnings conference call is scheduled for Tuesday, November 3, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Cumberland Pharmaceuticals? Analysts expect Cumberland Pharmaceuticals to post earnings of -$0.13 per share for Q3 2026. How much revenue is Cumberland Pharmaceuticals expected to report? The consensus revenue estimate for Cumberland Pharmaceuticals is $8.50 million for Q3 2026. Cumberland Pharmaceuticals Earnings HeadlinesCumberland Pharmaceuticals (NASDAQ:CPIX) Shares Cross Above 200 Day Moving Average - Here's What HappenedOctober 10, 2026 | americanbankingnews.comCumberland Pharmaceuticals Updates Ifetroban DMD Trial TimelineAugust 28, 2026 | tipranks.comFederal Reserve Reveals Disturbing New Plan To Control Your MoneyDocket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on page 84 is a plan that could expand oversight of checking accounts, purchases, and money transfers across the country. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what this document means and why it could roll out as soon as this summer.October 14 at 1:00 AM | Weiss Ratings (Ad)Cumberland Pharmaceuticals: Pivot Into Drug Development Creates Risk, OpportunityAugust 13, 2026 | seekingalpha.comCumberland Pharmaceuticals Inc. (CPIX) Q2 2026 Earnings Call TranscriptAugust 4, 2026 | seekingalpha.comCUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTSAugust 4, 2026 | prnewswire.comSee More Cumberland Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cumberland Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cumberland Pharmaceuticals and other key companies, straight to your email. Email Address About Cumberland PharmaceuticalsCumberland Pharmaceuticals (NASDAQ:CPIX) (NASDAQ:CPIX) is a specialty pharmaceutical company headquartered in Nashville, Tennessee. Founded in 1999, the company develops, acquires, and commercializes branded prescription products, with an emphasis on hospital acute care, gastroenterology, and other specialty areas. Its portfolio has included Caldolor, an intravenous formulation of ibuprofen used for pain and fever; Vaprisol, an injectable treatment for certain cases of hyponatremia; Kristalose, a prescription form of lactulose used to treat constipation; and Omeclamox-Pak, a therapy for Helicobacter pylori infection and associated ulcer disease. Cumberland has also marketed products such as Acetadote, an injectable treatment for acetaminophen overdose. The company primarily serves the U.S. healthcare market through its commercial organization and also pursues international distribution opportunities through strategic partners. Cumberland is led by A.J. Kazimi, who has served as its chief executive officer since the company's founding.View Cumberland Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Don’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American BusinessTax Credit Turmoil: Why Enphase and SolarEdge Face a Tough RoadSurgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based Strength Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
